All In Biotech

Drug Trial Radar · NCT04776018

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

27

Actual

Start

Apr 20, 2021

Primary completion

Aug 2, 2023

Study completion Nov 9, 2023

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D). Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions

  • TAK-981Drug

    TAK-981 IV infusion.

  • MezagitamabDrug

    Mezagitamab SC injection.

  • Daratumumab and Hyaluronidase-fihjDrug

    Daratumumab and Hyaluronidase-fihj SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b, Part 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of study drug through 30 days after the last dose of study drug (up to 13 months)
  2. Phase 1b, Part 1: Number of Participants With Grade 3 or Higher TEAEsTime frame: From the first dose of study drug through 30 days after the last dose of study drug (up to 13 months)
  3. Phase 1b, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) Based on NCI CTCAE Version 5.0Time frame: Cycle 1 (Cycle length = 28 Days)
  4. Phase 2: Overall Response Rate (ORR)Time frame: From date of treatment start to until date of first PD or death (whichever occurred first), up to 24 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona - PPDS

    Scottsdale, Arizona

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Mayo Clinic - Cancer Center - Rochester - PPDS

    Rochester, Minnesota

  • Oncology Hematology West (Omaha) - USOR

    Omaha, Nebraska

  • Weill Cornell Medical Center

    New York, New York

  • TriHealth Cancer Institute

    Cincinnati, Ohio

  • Baylor Sammons Cancer Center

    Dallas, Texas

  • Northeast Texas Cancer and Research Institute

    Tyler, Texas

  • Medical College of Wisconsin Cancer Center

    Milwaukee, Wisconsin

  • Hopital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.